Northwest Biotherapeutics, Inc. Sustainability Profile
Northwest Biotherapeutics, Inc. (often referred to as NW Bio) is a pioneering biotechnology company headquartered in the United States, with significant operational activities in the field of cancer immunotherapy. Founded in 2001, the company has made notable strides in developing innovative therapies, particularly its lead product, DCVax®-L, which is designed to treat various types of cancer by harnessing the body’s immune system. With a focus on personalised medicine, Northwest Biotherapeutics stands out in the biopharmaceutical industry for its unique approach to dendritic cell therapy. The company has achieved key milestones, including successful clinical trials that underscore its commitment to advancing cancer treatment. As a leader in the immunotherapy sector, NW Bio continues to position itself at the forefront of cancer research, aiming to improve patient outcomes and redefine therapeutic standards.
DitchCarbon Score
How does Northwest Biotherapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Northwest Biotherapeutics, Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Northwest Biotherapeutics, Inc.'s reported carbon emissions
Northwest Biotherapeutics, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year, nor does it report any specific reduction targets or initiatives. The company has not disclosed any commitments to climate pledges or frameworks such as the Science Based Targets initiative (SBTi). As a result, there are no specific figures or scopes of emissions (Scope 1, 2, or 3) to report. In the absence of concrete emissions data or reduction commitments, it is unclear how Northwest Biotherapeutics is addressing climate change or its carbon footprint. The company may need to enhance its transparency and engagement in climate-related initiatives to align with industry standards and expectations.
How Carbon Intensive is Northwest Biotherapeutics, Inc.'s Industry?
How Carbon Intensive is Northwest Biotherapeutics, Inc.'s Location?
Northwest Biotherapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Northwest Biotherapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
